Damascelli Bruno, Patelli Gian Luigi, Lanocita Rodolfo, Di Tolla Giuseppe, Frigerio Laura Francesca, Marchianò Alfonso, Garbagnati Francesco, Spreafico Carlo, Tichà Vladimira, Gladin Caroline Regna, Palazzi Mauro, Crippa Flavio, Oldini Cesare, Calò Stefano, Bonaccorsi Alberto, Mattavelli Franco, Costa Luigi, Mariani Luigi, Cantù Giulio
Department of Radiology, Istituto Nazionale Tumori, Via Venezian, 1, Milano 20133, Italy.
AJR Am J Roentgenol. 2003 Jul;181(1):253-60. doi: 10.2214/ajr.181.1.1810253.
The purpose of our study was to evaluate the effectiveness of intraarterial infusion of paclitaxel incorporated into human albumin nanoparticles for use as induction chemotherapy before definitive treatment of advanced squamous cell carcinoma of the tongue.
Twenty-three previously untreated patients (age range, 27-75 years) who had carcinoma of the tongue (stage T3-T4, any N) received intraarterial therapy with paclitaxel incorporated into albumin nanoparticles delivered by transfemoral catheterization into the external carotid artery (10 patients), selectively into the lingual artery (12 patients), or into a faciolingual trunk (1 patient). Each patient received two to four infusions, with a 3-week interval between infusions. The dose administered was 230 mg/m(2) in eight patients, 180 mg/m(2) in six patients, and 150 mg/m(2) in nine patients. Sixteen patients underwent surgery. Of these 16 patients, eight subsequently received radiotherapy, and three received a combination of chemotherapy and radiotherapy. Of the remaining seven patients, one received chemotherapy alone, four received radiotherapy alone, one received chemotherapy plus radiotherapy, and one refused any further treatment.
Sixty-seven infusions were performed successfully. Eighteen patients (78%) had a clinical and radiologic objective response (complete, 26%; partial, 52%). Three patients (13%) showed stable disease, and two (9%) showed disease progression. The four patients with complete clinical response who underwent surgery showed microscopic residual carcinoma measuring less than 1 mm in two patients, less than 5 mm in one patient, and less than 1 cm in one patient. The toxicities encountered were hematologic (grade 3) in two patients (8.6%) and neurologic (grade 4) in two patients (reversible paralysis of the facial nerve, 8.6%). Two catheter-related complications occurred: one reversible brachiofacial paralysis and one asymptomatic occlusion of the external carotid artery.
Intraarterial infusion of paclitaxel in albumin nanoparticles proved reproducible and effective and deserves further investigation as induction chemotherapy before definitive treatment of advanced tumors of the tongue, with a view to organ preservation.
我们研究的目的是评估动脉内输注载有紫杉醇的人白蛋白纳米粒作为晚期舌鳞状细胞癌确定性治疗前诱导化疗的有效性。
23例先前未接受过治疗的舌癌患者(年龄范围27 - 75岁,T3 - T4期,任何N分期)接受动脉内治疗,通过经股动脉导管插入术将载有紫杉醇的白蛋白纳米粒注入颈外动脉(10例患者)、选择性注入舌动脉(12例患者)或面舌干(1例患者)。每位患者接受两至四次输注,输注间隔为3周。8例患者的给药剂量为230mg/m²,6例患者为180mg/m²,9例患者为150mg/m²。16例患者接受了手术。在这16例患者中,8例随后接受了放疗,3例接受了化疗与放疗联合治疗。其余7例患者中,1例仅接受化疗,4例仅接受放疗,1例接受化疗加放疗,1例拒绝进一步治疗。
成功进行了67次输注。18例患者(78%)有临床和影像学客观反应(完全缓解,26%;部分缓解,52%)。3例患者(13%)疾病稳定,2例(9%)疾病进展。4例临床完全缓解且接受手术的患者中,2例显微镜下残余癌小于1mm,1例小于5mm,1例小于1cm。出现的毒性反应包括血液学毒性(3级)2例患者(8.6%)和神经学毒性(4级)2例患者(面神经可逆性麻痹,8.6%)。发生了2例与导管相关的并发症:1例可逆性臂面部麻痹和1例颈外动脉无症状性闭塞。
动脉内输注载有紫杉醇的白蛋白纳米粒被证明具有可重复性且有效,作为晚期舌肿瘤确定性治疗前的诱导化疗,有望实现器官保留,值得进一步研究。